Die Rolle des Anästhesisten bei Lebertransplantationen – präoperative Evaluation

Die präoperative Patientenevaluation vor einer Lebertransplantation (LTX) stellt den Anästhesisten vor eine Reihe von Herausforderungen. Unter anderem müssen aufgrund sehr unterschiedlicher Indikationen und Begleiterkrankungen Empfehlungen für die präoperative Vorbereitung der Patienten stets individuell angepasst werden. Dieser Beitrag widmet sich insbesondere der Erfassung von Komorbiditäten und der Risikoabschätzung bei Patienten zur LTX.

Abstract

Preoperative evaluation prior to listing for orthotopic liver transplantation (LT) requires a careful multidisciplinary approach with specialized teams including surgeons, hepatologists and anesthesiologists in order to improve short- and long-term clinical outcomes. Due to inadequate supply of donor organs and changing demographics, patients listed for LT have become older, sicker and share more comorbidities. As cardiovascular events are the leading cause for early mortality precise evaluation of risk factors is mandatory. This review focuses on the detection and management of coronary artery disease, cirrhotic cardiomyopathy, portopulmonary hypertension and hepatopulmonary syndrome in patients awaiting LT. Further insights are being given into scoring systems, patients with Acute-on-chronic-liver-failure (ACLF), frailty, NASH cirrhosis and into psychologic evaluation of patients with substance abuse.

Kernaussagen

• Die LTX ist die einzige wirksame Therapie bei Patienten mit ESLD.

• Der operative Eingriff stellt eine außerordentliche Belastung für die kardiovaskuläre Reserve des Patienten dar, die mit keinem anderen nicht kardiochirurgischen Eingriff vergleichbar ist.

• Das Patientenkollektiv ist sehr heterogen, da ein ESLD mit einer Vielzahl von Komorbiditäten einhergeht, die regelhaft mit extrahepatischen Organversagen vergesellschaftet sind.

• Die wichtigsten kardiovaskulären Begleiterkrankungen von Patienten mit ESLD sind die koronare Herzerkrankung, die zirrhotische Kardiomyopathie und die portopulmonale Hypertonie.

• Weitere häufige Komorbiditäten sind das hepatopulmonale und das hepatorenale Syndrom. Ebenso wie eine Fehlernährung im Sinne einer Überernährung (NASH) oder einer Malnutrition (Sarkopenie, Frailty) spielen sie eine wichtige Rolle für die Prognose von Patienten mit ESLD.

• Die Heterogenität der Patienten stellt den Anästhesisten und die weiteren Mitglieder der Transplantationskonferenz vor die anspruchsvolle Aufgabe, individuell angepasste Empfehlungen für die präoperative Vorbereitung der Patienten festzulegen. Hierzu müssen Chancen, Risiken und die Gesamtprognose gegeneinander abgewogen werden.

• Da es im Rahmen eines ESLD jederzeit zur Verschlechterung des Allgemeinzustandes oder einer Dekompensation der Leberfunktion kommen kann, sollte unmittelbar vor der Transplantation erneut eine Reevaluation stattfinden.

Schlüsselwörter

orthotope Lebertransplantation - präoperative Evaluation - Transplantationskonferenz - portopulmonale Hypertonie - hepatopulmonales Syndrom - hepatorenales Syndrom - akut-auf-chronisches Leberversagen - zirrhotische Kardiomyopathie - Frailty

Keywords

orthotopic liver transplantation - preoperative evaluation - transplantation conference - portopulmonary hypertension - hepatopulmonary syndrome - hepatorenal syndrome - acute-on-chronic liver failure - cirrhotic cardiomyopathy - frailty

Publication History

Article published online:
17 May 2024

• Literatur

• 1 Wigmore T, Gottumukkala V, Riedel B. Making the case for the subspecialty of onco-anesthesia. Int Anesthesiol Clin 2016; 54: 19-28
• 2 Hallet J, Jerath A, Turgeon AF. et al. Association between anesthesiologist volume and short-term outcomes in complex gastrointestinal cancer surgery. JAMA Surg 2021; 156: 479-487
• 3 Hofer I, Spivack J, Yaport M. et al. Association between anesthesiologist experience and mortality after orthotopic liver transplantation. Liver Transpl 2015; 21: 89-95
• 4 Geldner G, Karst J, Wappler B. et al. Präoperative Evaluation erwachsener Patienten vor elektiven, nicht herz-thoraxchirurgischen Eingriffen. Gemeinsame Empfehlung der DGAI, DGCH und DGIM. Anästh Intensivmed 2017; 58: 349-364
• 5 Martin P, DiMartini A, Feng S. et al. Evaluation for Liver Transplantation in Adults: 2013 Practice Guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59: 1114-1165
• 6 Bundesärztekammer. Richtlinien zur Organtransplantation gem. § 16 TPG. Dtsch Arztebl Ausg A 2019; 116: A-175
• 7 Bailey P, Vergis N, Allison M. et al. Psychosocial evaluation of candidates for solid organ transplantation. Transplantation 2021; 105: e292-e302
• 8 Duerinckx N, Burkhalter H, Engberg SJ. et al. Correlates and outcomes of posttransplant smoking in solid organ transplant recipients: a systematic literature review and meta-analysis. Transplantation 2016; 100: 2252-2263
• 9 Premkumar M, Anand AC. Tobacco, cigarettes, and the liver: the smoking gun. J Clin Exp Hepatol 2021; 11: 700-712
• 10 López-Lazcano AI, Gual A, Colmenero J. et al. Active smoking before liver transplantation in patients with alcohol use disorder: Risk factors and outcomes. J Clin Med 2020; 9: 2710
• 11 Goldberg DS, Olthoff KM. Standardizing MELD exceptions: Current challenges and future directions. Curr Transplant Rep 2014; 1: 232-237
• 12 Deutsche Stiftung Organtransplantation (DSO). DSO Jahresbericht. 2024 Accessed February 26, 2024 at: https://www.dso.de/organspende/statistiken-berichte/jahresbericht
• 13 Tovikkai C, Charman SC, Praseedom RK. et al. Time-varying impact of comorbidities on mortality after liver transplantation: a national cohort study using linked clinical and administrative data. BMJ Open 2015; 5: e006971
• 14 Mousa OY, Nguyen JH, Ma Y. et al. Evolving role of liver transplantation in elderly recipients. Liver Transpl 2019; 25: 1363-1374
• 15 Younossi ZM, Koenig AB, Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease- Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84
• 16 Sheka AC, Adeyi O, Thompson J. et al. Nonalcoholic steatohepatitis: a review. JAMA 2020; 323: 1175-1183
• 17 VanWagner LB, Lapin B, Levitsky J. et al. High early cardiovascular mortality after liver transplantation. Liver Transpl 2014; 20: 1306-1316
• 18 Xiao J, Yong JN, Han Ng C. et al. A meta-analysis and systematic review on the global prevalence, risk factors, and outcomes of coronary artery disease in liver transplantation recipients. Liver Transpl 2022; 28: 689-699
• 19 Busch MA, Kuhnert R. 12-Monats-Prävalenz einer koronaren Herzkrankheit in Deutschland. J Health Monit 2017; 2: 64-69
• 20 Hogan BJ, Gonsalkorala E, Heneghan MA. Evaluation of coronary artery disease in potential liver transplant recipients. Liver Transpl 2017; 23: 386-395
• 21 Nguyen P, Plotkin J, Fishbein TM. et al. Dobutamine stress echocardiography in patients undergoing orthotopic liver transplantation: a pooled analysis of accuracy, perioperative and long-term cardiovascular prognosis. Int J Cardiovasc Imaging 2013; 29: 1741-1748
• 22 Izzy M, VanWagner LB. Coronary artery disease assessment during evaluation for liver transplantation: How much does it matter?. Liver Transpl 2022; 28: 556-557
• 23 Satapathy SK, Vanatta JM, Helmick RA. et al. Outcome of liver transplant recipients with revascularized coronary artery disease: a comparative analysis with and without cardiovascular risk factors. Transplantation 2017; 101: 793-803
• 24 Izzy M, VanWagner LB, Lin G. et al. Redefining cirrhotic cardiomyopathy for the modern era. Hepatology 2020; 71: 334-345
• 25 Wong F, Liu P, Lilly L. et al. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond) 1999; 97: 259-267
• 26 Wiese S, Hove JD, Bendtsen F. et al. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol 2014; 11: 177-186
• 27 Barman PM, VanWagner LB. Cardiac risk assessment in liver transplant candidates: Current controversies and future directions. Hepatology 2021; 73: 2564-2576
• 28 Krowka MJ, Wiesner RH, Heimbach JK. Pulmonary contraindications, indications, and MELD exceptions for liver transplantation: a contemporary view and look forward. J Hepatol 2013; 59: 367-374
• 29 VanWagner LB, Harinstein ME, Runo JR. et al. Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: An evaluation of the evidence and consensus recommendations. Am J Transplant 2018; 18: 30-42
• 30 Swanson KL, Wiesner RH, Nyberg SL. et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008; 8: 2445-2453
• 31 Provencher S, Herve P, Jais X. et al. Deleterious effects of beta blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130: 120-126
• 32 Rodriguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome – a liver-induced lung vascular disorder. N Engl J Med 2008; 358: 2378-2387
• 33 Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology 2005; 41: 1122-1129
• 34 Lenci I, Alvior A, Manzia TM. et al. Saline contrast echocardiography in patients with hepatopulmonary syndrome awaiting liver transplantation. J Am Soc Echocardiogr 2009; 22: 89-94
• 35 Nayyar D, Man HSJ, Granton J. et al. Proposed management algorithm for severe hypoxemia after liver transplantation in the hepatopulmonary syndrome. Am J Transplant 2015; 15: 903-913
• 36 Kadry Z, Schaefer E, Krok K. et al. Excellent outcomes with liver transplantation in hepatopulmonary syndrome across pre-transplant PaO₂spectrum. JHEP Rep 2021; 3: 100351
• 37 Fede G, D’Amico G, Arvaniti V. et al. Renal failure, and cirrhosis: a systematic review of mortality and prognosis. J Hepatol 2012; 56: 810-818
• 38 Wong F, Nadim MK, Kellum JA. et al. Working party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011; 60: 702-709
• 39 Kim WR, Lake JR, Smith JM. et al. OPTN/SRTR 2015 annual data report: liver. Am J Transplant 2017; 17 (Suppl. 1) 174-251
• 40 LaMattina JC, Foley DP, Fernandez LA. et al. Complications associated with liver transplantation in the obese recipient. Clin Transplant 2012; 26: 910-918
• 41 VanWagner LB, Bhave M, Te HS. et al. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology 2012; 56: 1741-1750
• 42 Heinbokel T, Floerchinger B, Schmiderer A. et al. Obesity and its impact on transplantation and alloimmunity. Transplantation 2013; 96: 10-16
• 43 Aminian A, Al-Kurd A, Wilson R. et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA 2021; 326: 2031-2042
• 44 Verrastro O, Panunzi S, Castagneto-Gissey L. et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomized trial. Lancet 2023; 401: 1786-1797
• 45 Traub J, Reiss L, Aliwa B. et al. Malnutrition in patients with liver cirrhosis. Nutrients 2021; 13: 540
• 46 Laube R, Wang H, Park L. et al. Frailty in advanced liver disease. Liver Int 2018; 38: 2117-2128
• 47 Duong N, Sadowski B, Rangnekar AS. The impact of frailty, sarcopenia, and malnutrition on liver transplant outcomes. Clin Liver Dis (Hoboken) 2021; 17: 271-276
• 48 DiMartini A, Cruz Jr, Dew MA. et al. Muscle mass predicts outcomes following liver transplantation. Liver Transpl 2013; 19: 1172-1180
• 49 Kuo SZ, Ahmad M, Dunn MA. et al. Sarcopenia predicts post-transplant mortality in acutely ill men undergoing urgent evaluation and liver transplantation. Transplantation 2019; 103: 2312-2317
• 50 Lai JC, Feng S, Terrault NA. et al. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant 2014; 14: 1870-1879
• 51 Lai JC, Covinsky KE, Dodge JL. et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology 2017; 66: 564-574
• 52 Oikonomou IM, Sinakos E, Antoniadi N. et al. Effects of an active lifestyle on the physical frailty of liver transplant candidates. World J Transplant 2022; 12: 365-377
• 53 Knaak J, McVey M, Bazerbachi F. et al. Liver transplantation in patients with end-stage liver disease requiring intensive care unit admission and intubation. Liver Transpl 2015; 21: 761-767
• 54 Weiss E, Saner F, Asrani SK. et al. When Is a Critically Ill Cirrhotic Patient Too Sick to Transplant? Development of Consensus Criteria by a Multidisciplinary Panel of 35 International Experts. Transplantation 2021; 105: 561-568
• 55 Lai JC. Defining the threshold for too sick for transplant. Curr Opin Organ Transplant 2016; 21: 127-132
• 56 Petrowsky H, Rana A, Kaldas FM. et al. Liver transplantation in highest acuity recipients identifying factors to avoid futility. Ann Surg 2014; 259: 1186-1194
• 57 Moreau R, Jalan R, Gines P. et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144: 1426-1437
• 58 Michard B, Artzner T, Lebas B. et al. Liver transplantation in critically ill patients: Preoperative predictive factors of post-transplant mortality to avoid futility. Clin Transpl 2017; 31: e13115
• 59 Eurotransplant Datenbank. 2008–2018. Postmortal Donor. Liver only. Heart-beating Donor. Accessed February 26, 2024 at: https://www.eurotransplant.org/
• 60 Artzner T, Michard B, Besch C. et al. Liver transplantation for critically ill cirrhotic patients: Overview and pragmatic proposals. World J Gastroenterol 2018; 24: 5203-5214
• 61 Karvellas CJ, Francoz C, Weiss E. Liver transplantation in acute-on-chronic liver failure. Transplantation 2021; 105: 1471-1481
• 62 Sundaram V, Jalan R, Wu T. et al. Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation. Gastroenterology 2019; 156: 1381-1391.e3